Fig. 3

Loss of function of rab5ab. (A) Control embryo at 70% epiboly compared to (B) a 5 ng rab5ab MO-injected embryo at the same time point showing apparent accumulation of extracellular fluid between the yolk and the cells. (C) Control embryo at shield stage. (D) Animal view and (F) side view of a control-injected embryo at shield stage compared to (E) animal view and (G) side view of 3 ng rab5ab MO-injected embryos at the same time point. (H) Control-injected embryos at 90% epiboly compared to (I) the same time point in the 3 ng rab5ab MO-injected embryos. (J) 8 somite stage control embryo compared to (K) 3 ng rab5ab MO-injected embryo at the same time point. Expression pattern of gsc in (L) control MO-injected embryos (n=40/40) compared to (M) 3 ng rab5ab MO-injected embryos (n=41/41). Expression pattern of flh in (N) control MO-injected embryos (n=20/20) compared to (O) 3 ng rab5ab MO-injected embryos (n=21/21). Expression pattern of bhik in (P) control MO-injected embryos (n=29/29) compared to (Q) 3 ng rab5ab MO-injected embryos n=31/31). Expression pattern of ntl in (R) control MO-injected embryos (n=40/40) compared to (S) 3 ng rab5ab MO-injected embryos (n=39/39). Lateral view of expression pattern of ndr1 in (T) control MO-injected embryos (n=30/30) compared to (U) rab5ab MO-injected embryos (n=30/30). Lateral view of expression pattern of ndr2 in (V) control MO-injected embryos (n=30/30) compared to (W) rab5ab MO-injected embryos (n=29/29).